Juventas
Chaoyang
About Juventas
Juventas is a provider and developer of innovative immune cell therapeutic drugs. The company's first investigational new drug application for the cell therapeutic product CNCT19 has been officially accepted by the National Medical Products Administration. Comprehensive product pipelines will be developed and promoted constantly to provide effective treatment for malignant hematological neoplasms such as leukemia and lymphoma.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 51 – 100
- Estimated revenue: $1K – $10K
- Total funding: $101.6M
- Funding stage: Late Stage Venture
- Last round: Series C (Jul 2021)
- Website: juventas.cn
- Phone: 010-65960098
Industries & Categories
Biotechnology, Health Care, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/juventas-955 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.